Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.62 |
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.51 |
| ▸ | ALB | P02768 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23511301 | 0.90 | EGFR (0.54) | EGFRCA1CA2CA12CA9 | |
| SCHEMBL16005387 | 0.88 | EGFR (0.60) | EGFRCA1CA2CA12CA9 | |
| SCHEMBL15367533 | 0.86 | CA12 (0.60) | EGFRCA1CA2CA12CA9 | |
| SCHEMBL29385739 | 0.86 | CA12 (0.60) | EGFRCA1CA2CA12CA9 | |
| SCHEMBL16005243 | 0.85 | CA12 (0.48) | EGFRCA1CA2CA12CA9 | |
| SCHEMBL23511180 | 0.85 | CA12 (0.48) | EGFRCA1CA2CA12CA9 | |
| SCHEMBL28374017 | 0.81 | CA12 (0.45) | EGFRCA1CA2CA12CA9 | |
| SCHEMBL16005104 | 0.81 | EGFR (0.55) | EGFRCA1CA2CA12CA9 | |
| SCHEMBL16005098 | 0.77 | MAPT (0.46) | EGFRCA1CA2CA12CA9 | |
| SCHEMBL413095 | 0.77 | EGFR (1.00) | EGFRCA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2774914-B1 | N-BENZYLANILINE DERIVATIVE AND USES THEREOF | UNIV NANJING MEDICAL (CN) | 2017-12-06 | — | — | EP | disclosed |
| US-9481636-B2 | N-benzylaniline derivative and uses thereof | NANJING MEDICAL UNIVERSITY (CN) | 2016-11-01 | — | — | US | disclosed |
| CN-103086908-B | N-benzylaniline derivatives and application thereof | UNIV NANJING MEDICAL | 2015-05-13 | — | — | CN | disclosed |
| US-20140303248-A1 | N-BENZYLANILINE DERIVATIVE AND USES THEREOF | Neurodawn Pharmaceutical Co., Ltd. (CN) | 2014-10-09 | — | — | US | disclosed |
| EP-2774914-A1 | N-BENZYLANILINE DERIVATIVE AND USES THEREOF | Nanjing Medical University (CN) | 2014-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303248-A1 | N-BENZYLANILINE DERIVATIVE AND USES THEREOF | NLN, INA, TRPV1 | EGFR 4623/4885CA1 1325/4885CA2 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.